Highest-materiality recent filing
Statistically significant improvements on MDS-UPDRS Parts I, II, III and composite EPNIC-15 (p=0.0006).
Shareholders approve amended 2019 equity plan, increasing authorized shares to 3.1M
Amendment and restatement of 2019 Omnibus Equity Incentive Plan approved at annual meeting on Nov 10, 2025.
BioVie shareholders re-elect six directors, ratify auditor, approve equity plan increase
All 6 nominees elected for one-year terms; Amy Chappell received 1,517,109 for, 36,239 withhold.
BioVie raises ~$12M gross in public offering of units (stock + warrants) at $2.00/unit
Gross proceeds ~$12M from 6M units (5.62M shares + 380K pre-funded) at $2.00/unit.
BioVie appoints Amy Chappell and Kameel Farag to Board of Directors
Board expanded from 4 to 6 members; appointments effective July 17, 2025.
BioVie board effectuates 1-for-10 reverse stock split effective July 7, 2025
Reverse stock split ratio of 1-for-10 becomes effective at 12:01 am ET on July 7, 2025.
BioVie shareholders authorize reverse stock split at ratio of 1:5 to 1:10
8,664,435 voted for the reverse stock split authority, 2,200,874 against, 105,722 abstain.
BioVie board member Dr. Robert Hariri resigns effective March 28, 2025
Dr. Robert Hariri resigned from BioVie's Board of Directors on March 28, 2025.
BioVie shareholders approve equity plan increase to 1.25M shares; all directors elected
All six director nominees (Lang, Do, Sherman, Berman, Hariri, Rogich) elected with majorities.
BioVie prices $3.2M registered direct offering of 1.146M shares at $2.83/share
Offering of 1,146,000 shares at $2.83 per share, gross proceeds ~$3.2M.
BioVie closes registered direct offering raising $3.24M gross proceeds at $2.83/share
Closed registered direct offering of 1,146,000 shares at $2.83/share, gross proceeds ~$3.24M.
BioVie prices $6.0M registered direct offering at $2.25/share; issues warrants at $2.12
Gross proceeds of ~$6,000,750 from 2,667,000 shares of common stock at $2.25 per share.
BioVie closes $6M registered direct offering of 2.67M shares at $2.25/share with warrants
Closed offering of 2,667,000 shares at $2.25 per share for gross proceeds of $6,000,750.
BioVie prices $6.66M registered direct offering of 4.44M shares at $1.50/share
Gross proceeds of ~$6.66M from sale of 4,443,000 shares at $1.50/share in registered direct offering.
BioVie closes registered direct offering of 4.44M shares at $1.50, raising $6.66M gross
Closed registered direct offering of 4,443,000 shares at $1.50/share for gross proceeds of $6,664,500.
BioVie closes $3M public offering of shares and warrants at $1.53/unit
Closed best efforts offering of 1,360,800 shares, pre-funded warrants for 600,000 shares, and 1,960,800 common warrants.
BioVie files 8-K/A solely to replace legal opinion exhibit for Sept 2024 offering
Amendment corrects Exhibit 5.1; no changes to offering terms or other disclosures.
BioVie prices $3M public offering of 1.96M units at $1.53/share with warrants
Gross proceeds ~$3M from 1,960,800 units at $1.53 each; each unit includes share or pre-funded warrant plus 5-year warrant exercisable at $1.53.
BioVie regains Nasdaq minimum bid price compliance after 10-day $1 closing streak
Received Nasdaq compliance letter on August 20, 2024 for Bid Price Rule (5550(a)(2)).
BioVie files corrective certificates for 1:10 reverse stock split; terms unchanged
Filed Certificate of Amendment on Aug 2, 2024 to correct a defect in the original Certificate of Change.
BioVie shareholders approve 1-for-10 reverse stock split effective Aug 6, 2024
Stockholders approved reverse split ratio of 1-for-10; Board exercised authority on July 29, 2024.
Director Steve Gorlin resigns from BioVie board effective July 25, 2024
Steve Gorlin resigned as director of BioVie on July 25, 2024, effective immediately.
BioVie receives Nasdaq delisting notice; has 180 days to regain compliance
Nasdaq notified BioVie that its stock closed below $1.00 for 30 consecutive business days.
BioVie updates pipeline; plans Phase 2b PD trial summer 2024, delays AD Phase 3 to 2025
Raised $18.8M net ($21M gross) in equity financing to fund near-term priorities.
BioVie closes ~$21M public offering of stock and warrants
Issued 15M shares, pre-funded warrants for 6M shares, and common warrants for 10.5M shares at $1.00 combined price.
BioVie raises up to $21M in equity offering with warrants; files amendment to 8-K
Offering of up to 21 million shares of common stock at $1.00 per share.
BioVie announces $21M public offering of 21M shares at $1.00 with warrants
Offering of 21,000,000 common shares (or pre-funded warrants) at $1.00 per share, plus warrants to purchase up to 10,500,000 shares at $1.50.
PD Phase 2a: NE3107 improved sleep/fatigue NMSS domain -2.4 pts vs placebo +1.0 (p=0.0159); correlated with motor improvements.
BioVie hit with shareholder class action over NE3107 trial disclosures
Lawsuit filed Jan 19, 2024 in Nevada federal court (Olmstead v. BioVie Inc., No. 3:24-cv-00035).
BioVie files prospectus supplement for up to $25M ATM; already raised $59.4M from 8.1M shares
Filed prospectus supplement under new shelf registration (333-274083) for continued at-the-market sales of common stock.
BioVie Phase 3 NE3107 Alzheimer's trial misses primary endpoint; positive per-protocol trends
Primary endpoint missed statistical significance due to exclusion of patients from 15 sites with GCP violations; sites referred to FDA.
BioVie shareholders elect directors and ratify EisnerAmper as auditor
Shareholders elected all 7 director nominees: Cuong Do, Jim Lang, Michael Sherman, Richard J. Berman, Steve Gorlin, Robert Hariri, Sigmund Rogich.
BioVie presents blinded Phase 3 NE3107 data at CTAD; cognitive, biomarker improvements observed
Blinded data (n=322) show statistically significant population changes from baseline on ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, ADL.
BioVie updates investor presentation on September 8, 2023
Filed updated investor presentation (Exhibit 99.1) as of September 8, 2023.
BioVie terminates B. Riley as ATM agent; updates prior equity sales of $48.8M
Mutually terminated B. Riley as sales agent under Controlled Equity Offering Sales Agreement; Cantor Fitzgerald remains agent.
BioVie updates investor presentation on March 23, 2023; no specific details disclosed in filing
BioVie (BIVI) furnished an updated investor presentation as Exhibit 99.1 under Item 7.01.
BioVie board approves bylaw amendment on special meetings and director count
Chairman and CEO now authorized to call special board meetings with at least four hours' notice.
BioVie Chairman Terren Peizer resigns after being charged with insider trading of Ontrak Inc.
Resignation effective March 2, 2023; Peizer charged by DOJ and SEC for alleged insider trading of Ontrak Inc.
BioVie files prospectus supplement for $17.5M ATM offering; already raised $29M
Filed prospectus supplement on Dec 23, 2022 for up to $17.5M in Class A common stock sales.
BioVie files prospectus supplement for up to $17.5M ATM offering
At-the-market offering of up to $17.5M of Class A common stock via Cantor Fitzgerald & Co. and B. Riley Securities.
BioVie reports positive NE3107 data in Parkinson's, Alzheimer's, and aging biomarkers
NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone at 2-3 hours (clinically meaningful); 6+ points for patients <70.
BioVie increases ATM offering capacity from $8.1M to $17.5M under sales agreement
Filed prospectus supplement on Dec. 6, 2022 to raise maximum aggregate offering from $8.1M to $17.5M.
PD trial: NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone; under-70 patients saw 6-point superiority.
BioVie shareholders elect all 8 director nominees and ratify auditors at 2022 annual meeting
All eight director nominees (Terren Peizer, Cuong Do, Jim Lang, Michael Sherman, Richard Berman, Steve Gorlin, Robert Hariri, Sigmund Rogich) elected with high approval (23.78M–23.92M for).
82% of MCI/mild AD patients improved cognition (modified ADAS-Cog12) after 3 months; mean improvement -2.6 points (p=0.0046).
BioVie announces Phase 2 Alzheimer's results for NE3107 with cognitive and biomarker improvements
82% of 17 mild AD patients showed 2.6-point decrease in ADAS-Cog12 (p=0.046) after 3 months of NE3107.
23-patient open-label Phase 2: 82% of mild AD patients (MMSE>=20) showed mean 2.6-point ADAS-Cog12 improvement (p=0.0046); no drug-related adverse events.
BioVie enters $20M at-the-market equity sales agreement with Cantor and B. Riley
Up to $20M of Class A common stock may be sold through agents Cantor Fitzgerald and B. Riley in at-the-market offerings.
Issued 3,636,364 shares at $1.65/share to Acuitas Group Holdings, LLC, a related party controlled by chairman Terren Peizer.
BioVie raises $6M in private placement with controlling stockholder Acuitas Group
Sale of 3,636,364 shares at $1.65 plus warrant for 7,272,728 shares at $1.82 for aggregate $6M.
On March 28, 2025, Dr. Robert Hariri informed BioVie Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective as of such date.
On July 25, 2024, Steve Gorlin notified the Board of Directors (the “Board”) of BioVie Inc. (the “Company”) of his intention to resign as a director of the Company, effective immediately.
On March 2, 2023, BioVie Inc. (the “Company”) accepted the resignation of Terren S. Peizer, Chairman of the Board of Directors of the Company (the “Board”), effective immediately
The Board has elected Jim Lang, a current director of the Company, to serve as the new Chairman of the Board, effectively immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material